한글목차

신장암 치료제 세계 시장은 2024년 71억 5,000만 달러로 평가되었습니다. 예측 기간 동안 6.45%의 연평균 복합 성장률(CAGR)로 성장하여 2030년까지 강력한 성장을 보일 것으로 예상됩니다.

신장암은 신세포암으로도 알려져 있으며, 혈액 속 노폐물과 여분의 수분을 걸러 소변을 만드는 콩 모양의 기관인 신장에 발생하는 암의 일종입니다. 신장암은 의학적으로 신세포암(RCC)이라고 불리며, 효과적인 치료 전략이 필요한 복잡하고 어려운 질환입니다. 의학 연구의 발전과 의약품의 혁신이 가속화됨에 따라 몇 가지 주요 촉진요인이 신장암 치료제 시장의 성장과 진화를 촉진하고 있습니다. 표적치료제는 암세포의 성장과 생존에 필수적인 특정 분자나 경로를 억제하도록 설계된 약물의 한 유형입니다. 신장암의 경우, 표적치료제는 치료에 혁명을 일으켰습니다. 예를 들어, 수니티닙, 파조파닙, 악시티닙과 같은 티로신 키나아제 억제제(TKI)가 있습니다. 이 약제들은 종양의 성장과 혈관신생(새로운 혈관 형성)을 촉진하는 신호전달 경로를 파괴합니다. 이 약물의 도입으로 신장암 치료의 상황은 극적으로 변화했습니다. 과거에는 선택의 폭이 제한적이었던 환자들은 이제 생존율과 삶의 질을 향상시킬 수 있는 다양한 치료법을 이용할 수 있게 되었습니다. 연구가 진행됨에 따라 신장암 치료제 시장은 더 많은 진전을 이룰 것으로 보입니다. 병용요법, 개별화된 의료 접근법, 새로운 표적의 통합이 시야에 들어오고 있습니다. 또한 연구자, 제약회사, 의료 단체, 환자 지원 단체 간의 지속적인 협력 관계는 혁신적인 치료법 개발을 계속 형성하고 궁극적으로 신장암에 직면 한 환자의 결과를 개선하는 데 도움이 될 것입니다.

시장 성장 촉진요인

신장암 발병률 증가

주요 시장 이슈

내성과 치료의 불균일성

주요 시장 동향

개인 맞춤형 의료 혁명

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 신장암 치료제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 클래스별(표적치료, 면역치료, 화학요법)
  • 약리학적 클래스별(혈관신생 억제제, 단클론항체, mTOR 억제제, 사이토카인 면역치료(IL-2))
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 신장암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 신장암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 신장암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 신장암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 신장암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 PESTEL 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Genentech Inc.
• Bristol-Myers Squibb
• Eisai Co., Ltd.
• Exelixis Inc
• Prometheus Laboratories Inc
• Glaxosmithkline PLC.
• F. Hoffmann-LA Roche AG

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Kidney Cancer Drugs Market was valued at USD 7.15 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.45% through 2030. Kidney cancer, also known as renal cell carcinoma, is a type of cancer that originates in the kidneys, the bean-shaped organs responsible for filtering waste and excess fluids from the blood to form urine. Kidney cancer, medically termed renal cell carcinoma (RCC), is a complex and challenging disease that demands effective treatment strategies. As medical research advances and pharmaceutical innovation accelerates, several key drivers are propelling the growth and evolution of the kidney cancer drugs market. Targeted therapies are a class of drugs designed to inhibit specific molecules or pathways that are crucial for cancer cell growth and survival. In kidney cancer, targeted therapies have revolutionized treatment. Examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and axitinib. These drugs disrupt the signaling pathways that promote tumor growth and angiogenesis (formation of new blood vessels). The landscape of kidney cancer treatment has been dramatically transformed by the introduction of these drugs. Patients who once faced limited options now have access to a range of therapies that offer improved survival rates and enhanced quality of life. As research continues, the kidney cancer drugs market is poised for further advancements. Combination therapies, personalized medicine approaches, and the integration of novel targets are on the horizon. Additionally, the ongoing collaboration among researchers, pharmaceutical companies, healthcare organizations, and patient advocacy groups will continue to shape the development of innovative therapies and ultimately lead to better outcomes for patients facing kidney cancer.

Key Market Drivers

Rising Incidence of Kidney Cancer

The global kidney cancer market is experiencing significant expansion, largely driven by the rising incidence of kidney cancer worldwide. In 2022, kidney cancer accounted for 434,840 newly diagnosed cases globally, making it the 14th most prevalent cancer worldwide. It ranked as the 10th most diagnosed cancer among men and the 13th among women, underscoring its significant impact on global healthcare systems and oncology markets. The increasing number of renal cell carcinoma (RCC) cases-the most common type of kidney cancer-has created a growing demand for advanced diagnostics, innovative therapeutics, and improved healthcare infrastructure. This trend is not only shaping market dynamics but also influencing the strategic direction of pharmaceutical companies, healthcare providers, and investors. The global population is aging at an unprecedented rate. Between 1974 and 2024, the proportion of individuals aged 65 and older nearly doubled, rising from 5.5% to 10.3%, and age is a significant risk factor for kidney cancer. With higher life expectancy, the number of kidney cancer cases is expected to increase, driving demand for effective treatment options. Developed regions such as North America and Europe report higher incidence rates due to advanced screening programs and improved diagnostic capabilities. Meanwhile, emerging economies in Asia-Pacific are seeing rising cases due to lifestyle changes and increasing industrialization, leading to a higher demand for cancer therapeutics.

Key Market Challenges

Resistance and Treatment Heterogeneity

Despite the advancements in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Over time, tumors can evolve and adapt, rendering once-effective therapies ineffective. This challenge underscores the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Additionally, kidney cancer is not a homogeneous disease. Different subtypes and genetic variations contribute to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor that requires a deep understanding of tumor biology and personalized medicine approaches.

Key Market Trends

Personalized Medicine Revolution

The era of personalized medicine has dawned upon the field of kidney cancer treatment, offering immense promise for improved patient outcomes. With the advent of precision oncology, the one-size-fits-all approach to treatment is giving way to tailored interventions that account for individual genetic profiles and biomarker expression. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. Armed with this information, they can prescribe targeted therapies that are more likely to elicit a favorable response. This shift towards personalized treatment approaches not only enhances the efficacy of drugs but also minimizes the potential for adverse effects.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Genentech Inc.
• Bristol-Myers Squibb
• Eisai Co., Ltd.
• Exelixis Inc
• Prometheus Laboratories Inc
• Glaxosmithkline PLC.
• F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Kidney Cancer Drugs Market, By Therapeutic Class:

• Targeted Therapy
• Immunotherapy
• Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

• Angiogenesis Inhibitors
• Monoclonal Antibodies
• mTOR Inhibitors
• Cytokine Immunotherapy (IL-2)

Kidney Cancer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Kidney Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
  • 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Kidney Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Class
  • 6.2.2. By Pharmacologic Class
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Kidney Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Class
      • 6.3.1.2.2. By Pharmacologic Class
  • 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Class
      • 6.3.2.2.2. By Pharmacologic Class
  • 6.3.3. Canada Kidney Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Class
      • 6.3.3.2.2. By Pharmacologic Class

7. Europe Kidney Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value & Volume
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Class
  • 7.2.2. By Pharmacologic Class
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Kidney Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Class
      • 7.3.1.2.2. By Pharmacologic Class
  • 7.3.2. Germany Kidney Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Class
      • 7.3.2.2.2. By Pharmacologic Class
  • 7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Class
      • 7.3.3.2.2. By Pharmacologic Class
  • 7.3.4. Italy Kidney Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Class
      • 7.3.4.2.2. By Pharmacologic Class
  • 7.3.5. Spain Kidney Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Class
      • 7.3.5.2.2. By Pharmacologic Class

8. Asia-Pacific Kidney Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value & Volume
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Class
  • 8.2.2. By Pharmacologic Class
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Kidney Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Class
      • 8.3.1.2.2. By Pharmacologic Class
  • 8.3.2. India Kidney Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Class
      • 8.3.2.2.2. By Pharmacologic Class
  • 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Class
      • 8.3.3.2.2. By Pharmacologic Class
  • 8.3.4. Japan Kidney Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Class
      • 8.3.4.2.2. By Pharmacologic Class
  • 8.3.5. Australia Kidney Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Class
      • 8.3.5.2.2. By Pharmacologic Class

9. South America Kidney Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Class
  • 9.2.2. By Pharmacologic Class
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Class
      • 9.3.1.2.2. By Pharmacologic Class
  • 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Class
      • 9.3.2.2.2. By Pharmacologic Class
  • 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Class
      • 9.3.3.2.2. By Pharmacologic Class

10. Middle East and Africa Kidney Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Class
  • 10.2.2. By Pharmacologic Class
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Class
      • 10.3.1.2.2. By Pharmacologic Class
  • 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Class
      • 10.3.2.2.2. By Pharmacologic Class
  • 10.3.3. UAE Kidney Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Class
      • 10.3.3.2.2. By Pharmacologic Class

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Genentech Inc.
• 15.5. Bristol-Myers Squibb
• 15.6. Eisai Co., Ltd.
• 15.7. Exelixis Inc
• 15.8. Prometheus Laboratories Inc
• 15.9. Glaxosmithkline PLC.
• 15.10. F. Hoffmann-LA Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer